Condition deep-dive · 7 min read

POTS support — what supplements actually do for postural tachycardia

Updated 2026-05-15 · Reviewed by SupplementScore editors · No sponsorships

Postural orthostatic tachycardia syndrome (POTS) is defined by a sustained heart-rate increase of ≥30 bpm (or ≥40 bpm in adolescents) within 10 minutes of standing, in the absence of orthostatic hypotension, with symptoms of orthostatic intolerance. The pathophysiology spans hypovolemic, hyperadrenergic, and neuropathic subtypes. The supplement layer is unusually consistent for a complex disorder: aggressive sodium and fluid replacement is the cornerstone non-pharmacological intervention with consensus society support. Beyond that, deficiency-corrective supplementation (iron, B12, vitamin D) addresses common co-deficiencies that aggravate symptoms. The rest is adjunctive.

POTS is a clinical diagnosis that requires evaluation. Tachycardia + orthostatic intolerance has many causes — anaemia, dehydration, thyroid disease, autonomic neuropathy, mast cell activation, and structural cardiac issues. Tilt-table testing or active stand testing with HR/BP documentation is the standard. POTS care belongs with cardiology, autonomic specialists, or neurology — non-pharmacological measures are the foundation; pharmacological options (beta-blockers, ivabradine, midodrine, fludrocortisone, pyridostigmine) sit with the prescribing clinician.

What actually has trial evidence

Tier 1 evidence · Consensus society recommendation

Sodium chloride (table salt or oral rehydration salts)

8–10 g sodium chloride/day (≈3–4 g sodium), divided through the day

The 2015 Heart Rhythm Society consensus statement on POTS endorses high-dietary-sodium intake (≥10 g salt/day) as first-line non-pharmacological intervention. Mechanism: expansion of plasma volume, reduction of compensatory tachycardia. Garland 2015 and others showed objective expansion of plasma volume with high-sodium diet. Practical delivery: salt tablets (1 g each, 6–10/day), salt sticks, oral rehydration solutions (commercial WHO ORS formulations), or aggressive table-salt addition to food. Caution in patients with hypertension, heart failure, or renal disease — clinician supervision required.

Tier 1 evidence · Foundation alongside salt

Fluid intake (2.5–3 L/day water + ORS)

2.5–3 L/day total fluid; rapid 500 mL water bolus has documented acute pressor effect

High fluid intake supports plasma volume expansion alongside sodium loading. The "water bolus" — drinking 500 mL of cold water rapidly — has documented HR-lowering effect lasting 30–60 minutes (Jordan 2000); useful as acute symptomatic intervention before activities like standing in line or attending an event. Sip throughout the day rather than chugging.

Tier 2 evidence · Common comorbid deficiency

Iron (ferrous bisglycinate, if ferritin low)

25–30 mg elemental every other day with vitamin C, on empty stomach

Iron deficiency is markedly more common in POTS cohorts, particularly in menstruating women, and worsens tachycardia, fatigue, and exercise intolerance. Target ferritin >50–75 ng/mL in POTS, higher than the general-population threshold; Drs. Levine, Raj, and others have made the case for treating to a higher ferritin target in POTS specifically. Alternate-day dosing (Stoffel 2017) optimises absorption. Track haemoglobin and ferritin every 3–6 months during repletion.

Tier 2 evidence · Comorbid B12 issues common

Vitamin B12 (methylcobalamin if deficient)

1,000 mcg/day methylcobalamin if serum B12 <400 pg/mL or MMA elevated

B12 deficiency overlaps with POTS phenotype (fatigue, dizziness, paresthesia, cognitive symptoms). Serum B12 alone is insensitive; pair with methylmalonic acid for borderline values. Vegan diet, PPI use, and metformin all increase B12 deficiency risk. Supplement to target and reassess.

Tier 3 evidence · Muscle cramps, sleep, anxiety

Magnesium (glycinate or threonate)

200–400 mg elemental/day, evening

POTS patients often have prominent muscle cramps, poor sleep, and anxiety overlap; magnesium addresses all three modestly. No direct POTS-mechanism trial evidence, but the side-effect profile is benign and the symptom overlap warrants a trial. Use glycinate or threonate for sleep/cognitive endpoints; avoid magnesium oxide unless constipation is also a goal.

The lifestyle and behavioural base — most of POTS management

What to skip

What to track

Standing HR (10-minute stand or active-stand test) and orthostatic symptoms (Vanderbilt Orthostatic Symptom Score, COMPASS-31, or Malmö POTS Symptom Score) at baseline and at intervals. Daily salt and fluid intake logs (most patients underestimate by 30–50%). Ferritin and B12 at 6-month intervals during repletion. The bar for clinical response: standing HR rise reduced by ≥10 bpm, COMPASS-31 reduced by ≥5 points, and meaningful improvement in symptom-day frequency.

Practical quick-start. 10 g/day sodium chloride + 2.5–3 L/day fluids + 20–30 mmHg compression garments + Levine-protocol recumbent exercise progression. Test ferritin, B12, vitamin D, and TSH; supplement deficiencies. Add 500 mL water bolus before triggers (standing in line, getting out of a hot car). Reassess at 12 weeks. If non-pharmacological measures don't produce adequate improvement, pharmacological options (beta-blockers, ivabradine, midodrine, fludrocortisone, pyridostigmine) sit with cardiology/autonomic specialist.

Sources

Read more: